Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis
Open accessThe DOI matches its Crossref record; 230 of the 230 references it cites were found in a registry or an index.
Abstract
Neuromyelitis optica spectrum disorders (NMOSD) are autoantibody mediated chronic inflammatory diseases. Serum antibodies (Abs) against the aquaporin-4 water channel lead to recurrent attacks of optic neuritis, myelitis and/or brainstem syndromes. In some patients with symptoms of NMOSD, no AQP4-Abs but Abs against myelin-oligodendrocyte-glycoprotein (MOG) are detectable. These clinical syndromes are now frequently referred to as "MOG-encephalomyelitis" (MOG-EM). Here we give an overview on current recommendations concerning diagnosis of NMOSD and MOG-EM. These include antibody and further laboratory testing, MR imaging and optical coherence tomography. We discuss therapeutic options of acute attacks as well as longterm immunosuppressive treatment, including azathioprine, rituximab, and immunoglobulins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–230 of 230
Pandit, L., Mustafa, S., Nakashima, I., Takahashi, T., & Kaneko, K. (2018) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/2055217318787829 · Cited by 38
Optical coherence tomography for retinal imaging in multiple sclerosis
Zimmermann, H. G., Oberwahrenbrock, T., Brandt, A. U., Paul, F., & Dörr, J. (2014) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s73506 · Cited by 38
Self-citationAkaishi, T., Kaneko, K., Himori, N., Takeshita, T., Takahashi, T., Nakazawa, T., Aoki, M., & Nakashima, I. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.10.001 · Cited by 37
Dörr, J.-M., Bitsch, A., Schmailzl, K. J. G., Chan, A., von Ahsen, N., Hummel, M., Varon, R., Lill, C. M., Vogel, H.-P., Zipp, F., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b878f6 · Cited by 37
Self-citationContentti, E. C., Marques, V. D., de Castillo, I. S., Tkachuk, V. A., Barreira, A. A., Armas, E., Chiganer, E., Cruz, C. D. A., Pace, J. L. D., Hryb, J. P., et al. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.11.004 · Cited by 36 · cited 11×
“This can be helpful to diagnose MOG-EM or NMOSD in patients without AQP4-Abs (46, 77, 131, 134, 135).”
BackgroundInfluentialSpectrum of MRI brain lesion patterns in neuromyelitis optica spectrum disorder: a pictorial review
Wang, K. Y., Chetta, J. A., Bains, P., Balzer, A., Lincoln, J. A., Uribe, T., & Lincoln, C. M. M. (2018) · British Journal of Radiology · doi:10.1259/bjr.20170690 · Cited by 36
Progressive inner nuclear layer dysfunction in non-optic neuritis eyes in MS
You, Y., Graham, E. C., Shen, T., Yiannikas, C., Parratt, J. D. E., Gupta, V., Barton, J., Dwyer, M. G., Barnett, M. H., Fraser, C. L., et al. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000427 · Cited by 35
Prominent brainstem symptoms/signs in patients with neuromyelitis optica in a Taiwanese population
Wang, K., Lee, C.-L., Chen, S., Lin, K.-H., & Tsai, C. (2011) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2010.12.052 · Cited by 34 · cited 1×
“, area postrema syndrome or diencephalic syndrome can occur (8, 9).”
BackgroundZhangBao, J., Zhou, L., Li, X., Cai, T., Lu, J., Lü, C., Zhao, C., & Quan, C. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2016.11.010 · Cited by 33 · cited 1×
“In patients with AQP4-Abs, the most frequent symptoms at onset are optic neuritis in 37-54% of the patients, and LETM in 30–47% of the patients (26, 63, 64).”
BackgroundFoveal thinning in neuromyelitis optica: A sign of retinal astrocytopathy?
Yamamura, T., & Nakashima, I. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000347 · Cited by 32
Jarius, S., Paul, F., Ruprecht, K., & Wildemann, B. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6677-1 · Cited by 32 · cited 1×
“Next to routine laboratory tests, this includes differential blood count, blood sedimentation, folic acid, and vitamin B12 (111).”
MethodSelf-citationKillestein, J., van der Meer, M. L., Regelink, J. C., Huijgens, P. C., Polman, C. H., & Dörr, J. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d2b7de · Cited by 32
Evangelopoulos, M., Andreadou, E., Koutsis, G., Koutoulidis, V., Anagnostouli, M. C., Katsika, P., Evangelopoulos, D. S., Evdokimidis, I., & Kilidireas, C. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.11.016 · Cited by 30 · cited 1×
“As an alternative to a fixed dosage regimen every 6 months, monitoring of CD19+/CD20+ B-lymphocytes and administration of RTX in the case of reconstitution of these cells is possible (189, 190).”
BackgroundFrequent retinal ganglion cell damage after acute optic neuritis
Brandt, A. U., Specovius, S., Oberwahrenbrock, T., Zimmermann, H. G., Paul, F., & Costello, F. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.04.006 · Cited by 29
Self-citationPandit, L., Sato, D. K., Mustafa, S., Takahashi, T., D’Cunha, A., Malli, C., Sudhir, A., & Fujihara, K. (2016) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/2055217316675634 · Cited by 26
Longitudinal follow-up of vision in a neuromyelitis optica cohort
Bouyon, M., Collongues, N., Zéphir, H., Ballonzoli, L., Jeanjean, L., Lebrun‐Frénay, C., Chanson, J., Blanc, F., Fleury, M., Outteryck, O., et al. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513476562 · Cited by 25
Jelčić, I., Hanson, J. V. M., Lukas, S., Weber, K. P., Landau, K., Pless, M. L., Reindl, M., Weller, M., Martinꝉ, R., Lutterotti, A., et al. (2018) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000669 · Cited by 24
Contribution of blood vessels to retinal nerve fiber layer thickness in NMOSD
Oertel, F. C., Zimmermann, H. G., Mikolajczak, J., Weinhold, M., Kadas, E. M., Oberwahrenbrock, T., Pache, F. C., Bellmann–Strobl, J., Ruprecht, K., Paul, F., et al. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000338 · Cited by 24
Self-citationTemporal visual resolution and disease severity in MS
Ayadi, N., Dörr, J., Motamedi, S., Gawlik, K., Bellmann–Strobl, J., Mikolajczak, J., Brandt, A. U., Zimmermann, H. G., & Paul, F. (2018) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000492 · Cited by 18
Self-citationFan, M., Fu, Y., Su, L., Shen, Y., Wood, K., Yang, L., Liu, Y., & Shi, F. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.02.003 · Cited by 18
Hope for a rare disease: eculizumab in neuromyelitis optica
Paul, F. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70089-9 · Cited by 14 · cited 1×
“There were encouraging findings from an open label study where 12 out of 14 highly active patients became relapse-free by eculizumab treatment (240, 241).”
ResultSelf-citationAquaporin-4 IgG autoimmune syndrome and immunoreactivity associated with thyroid cancer
Soelberg, K. K., Larsen, S. R., Mørch, M. T., Thomassen, M., Brusgaard, K., Paul, F., Smith, T. J., Godballe, C., Grauslund, J., Lillevang, S. T., et al. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000252 · Cited by 14
Self-citationPushing the boundaries of neuromyelitis optica: Does antibody make the disease?
Kister, I., & Paul, F. (2015) · Neurology · doi:10.1212/wnl.0000000000001749 · Cited by 13
Self-citationReversible paraspinal muscle hyperintensity in anti-MOG antibody–associated transverse myelitis
Pandit, L., Mustafa, S., Uppoor, R., Nakashima, I., Takahashi, T., & Kaneko, K. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000412 · Cited by 13 · cited 1×
“Rarer clinical manifestations of NMOSD comprise narcolepsy, acute diencephalic syndrome or muscle affection (54, 55), while in MOG-EM extraneural involvement such as reversible paraspinal muscle hyperintensity have been described, as well as MOG-Abs in combined central and peripheral demyelination syndromes (56, 57).”
BackgroundFailure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab
Kowarik, M. C., Hoshi, M., Hemmer, B., & Berthele, A. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000208 · Cited by 13
Ruxolitinib treatment in a patient with neuromyelitis optica: A case report
Hodecker, S. C., Stellmann, J., Rosenkranz, S. C., Young, K. L., Holst, B., Friese, M. A., & Heesen, C. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000328 · Cited by 12
Secondary progression and innate immunity in NMO: A possible link to alemtuzumab therapy?
Fujihara, K., & Nakashima, I. (2014) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000038 · Cited by 9
Longitudinally extensive myelitis in MS mimicking neuromyelitis optica
Whittam, D. H., Bhojak, M., Das, K., & Jacob, A. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000333 · Cited by 7 · cited 1×
“Other causes for longitudinally extensive spinal cord LETM lesions include sarcoidosis or spondylotic myelopathy or rarely MS and need to be considered (112, 122, 123).”
BackgroundOptische Kohärenztomographie bei Neuromyelitis optica-Spektrum-Erkrankungen
Oertel, F. C., Zimmermann, H. G., Brandt, A. U., & Paul, F. (2017) · Der Nervenarzt · doi:10.1007/s00115-017-0444-6 · Cited by 5
Self-citationRituximab in Neuromyelitis Optica Spectrum Disorders
Kim, S., & Kim, H. J. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.5933 · Cited by 3
Cited by
Jarius, S., Paul, F., Weinshenker, B. G., Levy, M., Kim, H. J., & Wildemann, B. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0214-9 · Cited by 478
Self-citationRomán, G. C., Gracia, F., Torres, A., Palacios, A., Gracia, K., & Harris, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.653786 · Cited by 237
Agasing, A. M., Wu, Q., Khatri, B., Borisow, N., Ruprecht, K., Brandt, A. U., Gawde, S., Kumar, G., Quinn, J. L., Ko, R. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16625-7 · Cited by 98
Self-citationDavé, V. A., & Klein, R. S. (2023) · Glia · doi:10.1002/glia.24294 · Cited by 29
“…(MRI) of patients that have recovered from WNV, including those without neuroinvasive disease, report atrophy of the posterior cingulate and insular cortices, and the hippocampus and entorhinal regions in the temporal lobe (Rev in Borisow et al., 2018), as observed in AD (Ledig et al., 2018).”
BackgroundLin, T.-Y., Chien, C., Lu, A., Paul, F., & Zimmermann, H. G. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1982697 · Cited by 16
Self-citation
Metadata
- Authors
- Borisow, N., Mori, M., Kuwabara, S., Scheel, M., & Paul, F.
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2018-10-23
- Volume
- 9
- Pages
- 888-888
- ISSN
- 1664-2295 (ISSN-L)
- OpenAlex
- W2895290943
- Cited by
- 227
- References
- 230
- FWCI
- 20.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.